OSR Holdings acquires immunotherapy assets from Vaximm AG in restructuring deal

OSR Holdings agreed to purchase proprietary immunotherapy technology and VXM01 pipeline assets from Swiss affiliate Vaximm AG effective May 27, 2026. The transaction restructures intra-group intellectual property ownership to optimize tax treatment, with payment contingent on future milestone triggers under an existing license agreement.